Moreover, this response could be different in individuals with CML who are still on treatment with TKIs in comparison to those who discontinued therapy due to sustained deep molecular response (DMR, BCR::ABL levels ≤ 0.01%); it is uncertain if the immunomodulatory effect of TKIs persists after discontinuation as well as its impact on the response to the vaccine and the severity or incidence of breakthrough infections. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.